Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 0 | 54,757 | 198,110 | 320,060 | 244,301 |
| Cost of Goods | N/A | 53,619 | 48,460 | 30,537 | 4,065 |
| Gross Profit | N/A | 1,138 | 149,650 | 289,523 | 240,236 |
| Operating Expenses | 0 | 101,571 | 200,704 | 96,280 | 110,899 |
| Operating Income | N/A | -99,814 | -50,594 | 193,780 | 129,402 |
| Interest Expense | 0 | 11,404 | 12,157 | 20,221 | 18,267 |
| Other Income | 0 | 37,478 | 6,829 | 10,968 | -1,765 |
| Pre-tax Income | 0 | -73,740 | -55,922 | 184,527 | 109,370 |
| Income Tax | N/A | -3,049 | 12,937 | 73,826 | 45,711 |
| Net Income Continuous | N/A | -70,691 | -68,859 | 110,701 | 63,659 |
| Minority Interests | N/A | -280 | N/A | -47 | 53 |
| Net Income | $N/A | $-70,411 | $-68,859 | $110,748 | $63,606 |
| EPS Basic Total Ops | N/A | -0.59 | -0.47 | 0.71 | 0.39 |
| EPS Basic Continuous Ops | N/A | -0.60 | -0.47 | 0.71 | 0.39 |
| EPS Diluted Total Ops | N/A | -0.59 | -0.47 | 0.71 | 0.39 |
| EPS Diluted Continuous Ops | N/A | -0.60 | -0.47 | 0.71 | 0.39 |
| EPS Diluted Before Non-Recurring Items | N/A | 0.28 | 0.37 | 0.63 | 0.29 |
| EBITDA(a) | $N/A | $-82,405 | $-23,458 | $231,873 | $151,457 |